Cobertura de los medios
56
Cobertura de los medios
Nombre Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma Nombre/canal del medio de comunicación MENAFN -Press Releases (English) País/Territorio Jordania Fecha 13/02/23 Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Morningstar.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001107735&p=1gw&v=1&x=mfcAKhMthCW-sWVIcJiKMg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Street Insider País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001094734&p=1gw&v=1&x=J_uEO7fe6W7xR1rUoxvlMA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación BioSpace País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001479480&p=1gw&v=1&x=UAkS1rGp0dPHymTEG4bLng Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación InvestorsObserver País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001104781&p=1gw&v=1&x=MORWVid0-ldZFc2aXBpqOA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Finanzen.net País/Territorio Alemania Fecha 13/02/23 URL ct.moreover.com/?a=50001104888&p=1gw&v=1&x=Ho3vqzI6lnHy3k45T0k4bQ Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-yearsâ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Finanzen.ch País/Territorio Suiza Fecha 13/02/23 URL ct.moreover.com/?a=50001120910&p=1gw&v=1&x=sjXcszcsqMUnFhMYtsUpFg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Finanzen.ch País/Territorio Suiza Fecha 13/02/23 URL ct.moreover.com/?a=50001141204&p=1gw&v=1&x=cWeNcmBQmS5loanAuh-pkQ Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Yahoo! Finance País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001155243&p=1gw&v=1&x=c1LgGXS1_pvcbzv4eP0ghg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Yahoo! Finance UK and Ireland País/Territorio Reino Unido Fecha 13/02/23 URL ct.moreover.com/?a=50001170812&p=1gw&v=1&x=U7SAlQQgF-7wyjHMAdZEVQ Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Le Lezard.com País/Territorio Canadá Fecha 13/02/23 URL ct.moreover.com/?a=50001088842&p=1gw&v=1&x=gxyt6ptx0PMnH58khLOnsA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación MarketScreener.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001099261&p=1gw&v=1&x=6MAdXTrIrxFRJ2cSfOZHAA Personas Mauricio Burotto Nombre Cabometyx(R) in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación TD Ameritrade País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001094478&p=1gw&v=1&x=7zHjOgM-Kvhacf4e7HadwQ Personas Mauricio Burotto Nombre Cabometyx in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Wallstreet Online País/Territorio Alemania Fecha 13/02/23 URL ct.moreover.com/?a=50001145504&p=1gw&v=1&x=YhuTPENn_qU-FNWaAM44YQ Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Valuespectrum.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001244540&p=1gw&v=1&x=4NKwwhhSiThoMvx24h5Ecw Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación GlobeNewswire País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001107717&p=1gw&v=1&x=4qk0CDfFSUTh4yIpJvc4TQ Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Yahoo! Sports País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001118849&p=1gw&v=1&x=N8w-mVcnwXgLSR_Qvvo1_Q Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación PrimeNewswire (Top News) País/Territorio Estados Unidos Fecha 13/02/23 Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Investegate País/Territorio Reino Unido Fecha 13/02/23 URL ct.moreover.com/?a=50001097990&p=1gw&v=1&x=4PvL8O8lkSCIW_SEAJGD6g Personas Mauricio Burotto Nombre Ipsen SA: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma (GlobeNewswire) Nombre/canal del medio de comunicación Avanza Bank AB País/Territorio Suecia Fecha 13/02/23 URL ct.moreover.com/?a=50001101856&p=1gw&v=1&x=VkBBihh6AYxHzwvkEafRQg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Ipsen País/Territorio Francia Fecha 13/02/23 URL ct.moreover.com/?a=50001188774&p=1gw&v=1&x=WtpjbU2Cvd_3-9ZVTfvQeA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Nombre/canal del medio de comunicación Port Arthur News País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001131587&p=1gw&v=1&x=MUEEdvFNLCi3P6uhqo0Q5w Personas Mauricio Burotto Nombre Ipsen Pharma: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación FinanzNachrichten.de País/Territorio Alemania Fecha 13/02/23 URL ct.moreover.com/?a=50001173110&p=1gw&v=1&x=LkUZ3NpG4zJGWozVqKh33g Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Nombre/canal del medio de comunicación Winchester Sun País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001145863&p=1gw&v=1&x=ypuv-6XItoULcHJjenBtNw Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Nombre/canal del medio de comunicación Smithfield Times País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001152309&p=1gw&v=1&x=AaRmt0breGybB2ASC8HS6A Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Nombre/canal del medio de comunicación Jessamine Journal País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001153417&p=1gw&v=1&x=SOp8mZxLjmEehZwTvmvbRg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Nombre/canal del medio de comunicación Suffolk News Herald País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001156276&p=1gw&v=1&x=ieodvdhlz07Lr0rKt2NLXg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WIVB País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001161296&p=1gw&v=1&x=cP_YAA9aeA6hk-NRVeIh-g Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Nombre/canal del medio de comunicación Elizabethton.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001169817&p=1gw&v=1&x=EnINAe7YPKUreL_xdmdQWg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Nombre/canal del medio de comunicación LaGrange Daily News País/Territorio Georgia Fecha 13/02/23 URL ct.moreover.com/?a=50001170723&p=1gw&v=1&x=2rmnm2sdCQGX2jeMMR0Ufg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WTWO País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001171504&p=1gw&v=1&x=ADKYd7D5O-VuNQS74R4tzA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Nombre/canal del medio de comunicación Tryon Daily Bulletin País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001172200&p=1gw&v=1&x=gReVEtsRMeOdl-Hf2hBMbQ Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación KOIN País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001174875&p=1gw&v=1&x=XQtrK6YVNYdDGBK-Wu6NLA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación NBC4 Columbus País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001198270&p=1gw&v=1&x=6ulvScxiENnn0ymyd380rA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación FOX5 San Diego País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001238761&p=1gw&v=1&x=UjH_MzTwaUh8gbtBdHD1zg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WKBN 27 First News País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001250398&p=1gw&v=1&x=4niJ58ApAZGf21JfRjhjAQ Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación BRProud.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001259780&p=1gw&v=1&x=e5rEGkNPiLQ2_kZvdCJMUA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación BizWire Express País/Territorio India Fecha 13/02/23 URL ct.moreover.com/?a=50001265664&p=1gw&v=1&x=hWfELWXMmuzYs6QOYHrIVA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación PIX11 País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001280387&p=1gw&v=1&x=-sBW5Actiq8TTyxB7h86QA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WGNO País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001302570&p=1gw&v=1&x=pqb0yRW5s8XCb3PxIvp1-g Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación YOUR BASIN País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001304035&p=1gw&v=1&x=qpYWV-8U1Uxw-Nni8Dwa0g Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WJHL.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001310281&p=1gw&v=1&x=eQpHRNfh3bXW_Rg58yo31Q Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación KTLA País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001316027&p=1gw&v=1&x=Vx5svUUmbvU3IMwCLkMZHg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WGN-TV País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001319362&p=1gw&v=1&x=rIWrSa14TBhMIzReWHwoiw Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Wood TV País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001325299&p=1gw&v=1&x=H_EpkB_JJsVvxPwt4248Iw Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Siouxland Matters País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001332225&p=1gw&v=1&x=EXF2wNEGKxDUt43LYDo3rw Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WTen.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001341003&p=1gw&v=1&x=_ArHKOtbXTs3D4-zbh3TDA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Fox 16 País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001343999&p=1gw&v=1&x=y8u3ufu1HHaBwgp_vk-jrA Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación FOX8 WGHP País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001375138&p=1gw&v=1&x=CPc6kMppyaSHuS1-xADywg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WREG País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001375366&p=1gw&v=1&x=u7vBUx97XDE62V61fSMPjg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación Everything Lubbock País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001380084&p=1gw&v=1&x=HmbuGssESmrLY60VK9Lsew Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación WANE-TV País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001389348&p=1gw&v=1&x=BdiF9WVSWvaWo2FH77aa9w Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación MyPanhandle.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001401213&p=1gw&v=1&x=d-5oi2kGrw7zHNS5zhQ3Bg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Nombre/canal del medio de comunicación KFOR.com País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001414213&p=1gw&v=1&x=F6J7QUwMdPZl5LG9PM0GDg Personas Mauricio Burotto Nombre Cabometyx® in combination with nivolumab shows durable Nombre/canal del medio de comunicación Life Care News País/Territorio India Fecha 13/02/23 URL ct.moreover.com/?a=50001679155&p=1gw&v=1&x=BiB6yihxmG7zNiSJUctRTA Personas Mauricio Burotto Nombre Cabometyx in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line Nombre/canal del medio de comunicación User Walls País/Territorio Estados Unidos Fecha 13/02/23 URL ct.moreover.com/?a=50001099632&p=1gw&v=1&x=pBBjBpX3gMAxYuZuYXnVIA Personas Mauricio Burotto